(Post-pandemic Era)-Global Psychoactive Substances Market Segment Research Report 2022
- Published Date: 2022-04-19
- Report ID: 128237
- Pages: 175
-
Format:
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Beijing Yanjing Bizhi Information Consulting Co., Ltd. XYZResearchreleased the Global Psychoactive Substances Market Segment Research Report 2022, which aims to sort out the development status and trends of the Psychoactive Substances industry at home and abroad, estimate the overall market scale of the Psychoactive Substances industry and the market share of major countries, analyze the development potential of each segment of the Psychoactive Substances industry, and study and judge the downstream market demand of Psychoactive Substances through systematic research, Analyze the competition pattern of Psychoactive Substances, so as to help solve the pain points of various stakeholders in Psychoactive Substances industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2017 - 2027) of Psychoactive Substances Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Psychoactive Substances Market
Zynerba Pharmaceuticals
GW Pharmaceuticals PLC.
Enecta.
Teewinot Life Sciences
GD Pharma
Cape Bouvard Technologies Pty Ltd
AusCann Group Holdings Pty Ltd.
Cannabics Pharmaceuticals Inc.
Alpha-CAT
Tilray
Cyrelian Pty Ltd.
MedReleaf Australia
Major Type of Psychoactive Substances Covered in XYZResearch report:
Stimulants
Cannabinoids
Hallucinogens
Depressants
Application Segments Covered in XYZResearch Market
Cancer
Neuropathic Disorders
Spasticity
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Psychoactive Substances Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Psychoactive Substances Market by Value
2.2.1 Global Psychoactive Substances Revenue by Type
2.2.2 Global Psychoactive Substances Market by Value (%)
2.3 Global Psychoactive Substances Market by Production
2.3.1 Global Psychoactive Substances Production by Type
2.3.2 Global Psychoactive Substances Market by Production (%)
3. The Major Driver of Psychoactive Substances Industry
3.1 Historical & Forecast Global Psychoactive Substances Demand
3.2 Largest Application for Psychoactive Substances (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Psychoactive Substances Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2019-2027)
4.3 Concentration Ratio (CR5& CR10) of Psychoactive Substances Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Psychoactive Substances Production, Demand (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Psychoactive Substances Production, Demand (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Psychoactive Substances Production, Demand (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Psychoactive Substances Production, Demand (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Psychoactive Substances Production, Demand (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Psychoactive Substances Production, Demand (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Psychoactive Substances Production, Demand (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. Global Psychoactive Substances Average Price Trend
12.1 Market Price for Each Type of Psychoactive Substances in US (2018-2022)
12.2 Market Price for Each Type of Psychoactive Substances in Europe (2018-2022)
12.3 Market Price for Each Type of Psychoactive Substances in China (2018-2022)
12.4 Market Price for Each Type of Psychoactive Substances in Japan (2018-2022)
12.5 Market Price for Each Type of Psychoactive Substances in India (2018-2022)
12.6 Market Price for Each Type of Psychoactive Substances in Korea (2018-2022)
12.7 Market Price for Each Type of Psychoactive Substances in Southeast Asia (2018-2022)
13. Industrial Chain (Impact of COVID-19)
13.1 Psychoactive Substances Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Technology Trends of Psychoactive Substances
14. Psychoactive Substances Competitive Landscape
14.1 Zynerba Pharmaceuticals
14.1.1 Zynerba Pharmaceuticals Company Profiles
14.1.2 Zynerba Pharmaceuticals Product Introduction
14.1.3 Zynerba Pharmaceuticals Psychoactive Substances Sales, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 GW Pharmaceuticals PLC.
14.2.1 GW Pharmaceuticals PLC. Company Profiles
14.2.2 GW Pharmaceuticals PLC. Product Introduction
14.2.3 GW Pharmaceuticals PLC. Psychoactive Substances Sales, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Enecta.
14.3.1 Enecta. Company Profiles
14.3.2 Enecta. Product Introduction
14.3.3 Enecta. Psychoactive Substances Sales, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Teewinot Life Sciences
14.4.1 Teewinot Life Sciences Company Profiles
14.4.2 Teewinot Life Sciences Product Introduction
14.4.3 Teewinot Life Sciences Psychoactive Substances Sales, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 GD Pharma
14.5.1 GD Pharma Company Profiles
14.5.2 GD Pharma Product Introduction
14.5.3 GD Pharma Psychoactive Substances Sales, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Cape Bouvard Technologies Pty Ltd
14.6.1 Cape Bouvard Technologies Pty Ltd Company Profiles
14.6.2 Cape Bouvard Technologies Pty Ltd Product Introduction
14.6.3 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Sales, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 AusCann Group Holdings Pty Ltd.
14.7.1 AusCann Group Holdings Pty Ltd. Company Profiles
14.7.2 AusCann Group Holdings Pty Ltd. Product Introduction
14.7.3 AusCann Group Holdings Pty Ltd. Psychoactive Substances Sales, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Cannabics Pharmaceuticals Inc.
14.8.1 Cannabics Pharmaceuticals Inc. Company Profiles
14.8.2 Cannabics Pharmaceuticals Inc. Product Introduction
14.8.3 Cannabics Pharmaceuticals Inc. Psychoactive Substances Sales, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Alpha-CAT
14.9.1 Alpha-CAT Company Profiles
14.9.2 Alpha-CAT Product Introduction
14.9.3 Alpha-CAT Psychoactive Substances Sales, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Tilray
14.10.1 Tilray Company Profiles
14.10.2 Tilray Product Introduction
14.10.3 Tilray Psychoactive Substances Sales, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Cyrelian Pty Ltd.
14.12 MedReleaf Australia
15. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
